JP2017141277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017141277A5 JP2017141277A5 JP2017075145A JP2017075145A JP2017141277A5 JP 2017141277 A5 JP2017141277 A5 JP 2017141277A5 JP 2017075145 A JP2017075145 A JP 2017075145A JP 2017075145 A JP2017075145 A JP 2017075145A JP 2017141277 A5 JP2017141277 A5 JP 2017141277A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- pharmaceutical composition
- pain
- formulation
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 238000009472 formulation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960003299 ketamine Drugs 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10006202.5 | 2010-06-15 | ||
| EP10006202 | 2010-06-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015151003A Division JP6197007B2 (ja) | 2010-06-15 | 2015-07-30 | 痛み治療用の医薬配合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017141277A JP2017141277A (ja) | 2017-08-17 |
| JP2017141277A5 true JP2017141277A5 (enExample) | 2017-10-05 |
| JP6423036B2 JP6423036B2 (ja) | 2018-11-14 |
Family
ID=42395008
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013514579A Expired - Fee Related JP6133772B2 (ja) | 2010-06-15 | 2011-06-14 | 痛み治療用の医薬配合物 |
| JP2015151003A Expired - Fee Related JP6197007B2 (ja) | 2010-06-15 | 2015-07-30 | 痛み治療用の医薬配合物 |
| JP2017075145A Expired - Fee Related JP6423036B2 (ja) | 2010-06-15 | 2017-04-05 | 痛み治療用の医薬配合物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013514579A Expired - Fee Related JP6133772B2 (ja) | 2010-06-15 | 2011-06-14 | 痛み治療用の医薬配合物 |
| JP2015151003A Expired - Fee Related JP6197007B2 (ja) | 2010-06-15 | 2015-07-30 | 痛み治療用の医薬配合物 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8846765B2 (enExample) |
| EP (2) | EP2992877A1 (enExample) |
| JP (3) | JP6133772B2 (enExample) |
| KR (1) | KR101831616B1 (enExample) |
| CN (1) | CN103108631B (enExample) |
| AR (1) | AR081931A1 (enExample) |
| AU (2) | AU2011267474B2 (enExample) |
| BR (1) | BR112012031836A2 (enExample) |
| CA (1) | CA2796774C (enExample) |
| CL (1) | CL2012002551A1 (enExample) |
| CO (1) | CO6602157A2 (enExample) |
| CY (1) | CY1117118T1 (enExample) |
| DK (1) | DK2582366T3 (enExample) |
| EC (2) | ECSP12012217A (enExample) |
| ES (1) | ES2560676T3 (enExample) |
| HK (1) | HK1215787A1 (enExample) |
| HR (1) | HRP20151327T1 (enExample) |
| HU (1) | HUE026619T2 (enExample) |
| IL (1) | IL221926A (enExample) |
| MX (1) | MX2012014482A (enExample) |
| NZ (1) | NZ602625A (enExample) |
| PE (2) | PE20130243A1 (enExample) |
| PL (1) | PL2582366T3 (enExample) |
| PT (1) | PT2582366E (enExample) |
| RS (1) | RS54439B1 (enExample) |
| RU (2) | RU2589692C2 (enExample) |
| SI (1) | SI2582366T1 (enExample) |
| WO (1) | WO2011157391A1 (enExample) |
| ZA (1) | ZA201208646B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6133772B2 (ja) | 2010-06-15 | 2017-05-24 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 痛み治療用の医薬配合物 |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| WO2013138322A1 (en) * | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| RS59687B1 (sr) | 2013-01-22 | 2020-01-31 | Vistagen Therapeutics Inc | Oblici doziranja i terapeutske primene l-4-hlorkinurenina |
| AU2014240102A1 (en) | 2013-03-15 | 2015-09-17 | Janssen Pharmaceutica Nv | Pharmaceutical composition of S-ketamine hydrochloride |
| CN103655523A (zh) * | 2013-12-24 | 2014-03-26 | 南京艾德凯腾生物医药有限责任公司 | 他喷他多组合物 |
| MX2016014581A (es) * | 2014-05-06 | 2018-02-16 | Univ Northwestern | Composiciones de compuestos que modulan nmdar. |
| CA2957926A1 (en) | 2014-08-13 | 2016-02-18 | Janssen Pharmaceutica Nv | Method for the treatment of depression |
| AU2015318123A1 (en) | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| IL319020A (en) | 2017-12-22 | 2025-04-01 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| WO2019200345A1 (en) | 2018-04-12 | 2019-10-17 | Anavex Life Sciences Corp. | A2-73 crystalline polymorph compositions of matter and methods of use thereof |
| WO2020178653A1 (en) | 2019-03-05 | 2020-09-10 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| US5330761A (en) | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
| US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
| DE4426245A1 (de) * | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| US6248789B1 (en) * | 1996-08-29 | 2001-06-19 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
| US6007841A (en) * | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
| WO2000003716A1 (en) | 1998-07-16 | 2000-01-27 | Memorial Sloan-Kettering Cancer Center | Topical compositions comprising an opioid analgesic and an nmda antagonist |
| DE10005302A1 (de) * | 2000-02-07 | 2002-01-17 | Gruenenthal Gmbh | Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate |
| US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| PE20030527A1 (es) * | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| DE10163421A1 (de) * | 2001-12-21 | 2003-07-31 | Gruenenthal Gmbh | Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum |
| JP2003201254A (ja) * | 2001-12-28 | 2003-07-18 | Hisamitsu Pharmaceut Co Inc | 鎮痛剤活性増強剤の治療上有効な血中濃度を維持するための製剤 |
| JP2003210254A (ja) * | 2002-01-18 | 2003-07-29 | Nihon Form Service Co Ltd | 車椅子専用ラック |
| US20060240128A1 (en) | 2002-09-09 | 2006-10-26 | Schlagheck Thomas G | Combined immediate release and extended release analgesic composition |
| US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| US20090082466A1 (en) * | 2006-01-27 | 2009-03-26 | Najib Babul | Abuse Resistant and Extended Release Formulations and Method of Use Thereof |
| PL2012763T3 (pl) | 2006-04-28 | 2011-08-31 | Gruenenthal Gmbh | Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenol i NSAID |
| WO2007128413A1 (en) | 2006-04-28 | 2007-11-15 | Grünenthal GmbH | Pharmaceutical combination comprising 3- ( 3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol |
| US20070254960A1 (en) | 2006-04-28 | 2007-11-01 | Gruenenthal Gmbh | Pharmaceutical combination |
| EP1857463A1 (en) | 2006-05-03 | 2007-11-21 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Peptide having neuroprotective effects |
| WO2007141018A1 (en) | 2006-06-08 | 2007-12-13 | Schwarz Pharma Ag | Therapeutic combination for painful medical conditions |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| DE102007012165A1 (de) * | 2007-03-12 | 2008-09-18 | Grünenthal GmbH | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes |
| CN102065852B (zh) * | 2007-11-23 | 2015-06-17 | 格吕伦塔尔有限公司 | 他喷他多组合物 |
| US7872046B2 (en) * | 2008-01-25 | 2011-01-18 | Xenoport, Inc. | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
| JP5774853B2 (ja) | 2008-01-25 | 2015-09-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 医薬投薬形 |
| US20100190752A1 (en) | 2008-09-05 | 2010-07-29 | Gruenenthal Gmbh | Pharmaceutical Combination |
| HUE043278T2 (hu) * | 2008-09-05 | 2019-08-28 | Gruenenthal Gmbh | 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolt és pregabalint vagy gabapentint tartalmazó gyógyszerkombináció |
| JP6133772B2 (ja) | 2010-06-15 | 2017-05-24 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 痛み治療用の医薬配合物 |
| MX2013003354A (es) | 2010-09-21 | 2013-06-24 | Purdue Pharma Lp | Analogos de buprenorfina. |
| CA2991216C (en) | 2010-12-22 | 2020-04-28 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
| EA024193B1 (ru) | 2011-03-04 | 2016-08-31 | Грюненталь Гмбх | Фармацевтическая композиция на водной основе, предназначенная для парентерального введения тапентадола |
| MX2014011855A (es) | 2012-04-17 | 2016-09-09 | Purdue Pharma Lp | Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides. |
-
2011
- 2011-06-14 JP JP2013514579A patent/JP6133772B2/ja not_active Expired - Fee Related
- 2011-06-14 BR BR112012031836A patent/BR112012031836A2/pt active Search and Examination
- 2011-06-14 ES ES11730199.4T patent/ES2560676T3/es active Active
- 2011-06-14 PE PE2012002241A patent/PE20130243A1/es active IP Right Grant
- 2011-06-14 DK DK11730199.4T patent/DK2582366T3/en active
- 2011-06-14 PE PE2016000337A patent/PE20160531A1/es unknown
- 2011-06-14 CN CN201180029405.2A patent/CN103108631B/zh not_active Expired - Fee Related
- 2011-06-14 KR KR1020127032555A patent/KR101831616B1/ko not_active Expired - Fee Related
- 2011-06-14 PT PT117301994T patent/PT2582366E/pt unknown
- 2011-06-14 CA CA2796774A patent/CA2796774C/en not_active Expired - Fee Related
- 2011-06-14 RS RS20150842A patent/RS54439B1/sr unknown
- 2011-06-14 HR HRP20151327TT patent/HRP20151327T1/hr unknown
- 2011-06-14 PL PL11730199T patent/PL2582366T3/pl unknown
- 2011-06-14 AR ARP110102069A patent/AR081931A1/es not_active Application Discontinuation
- 2011-06-14 AU AU2011267474A patent/AU2011267474B2/en not_active Ceased
- 2011-06-14 NZ NZ602625A patent/NZ602625A/en not_active IP Right Cessation
- 2011-06-14 MX MX2012014482A patent/MX2012014482A/es active IP Right Grant
- 2011-06-14 RU RU2013101515/15A patent/RU2589692C2/ru active
- 2011-06-14 US US13/159,845 patent/US8846765B2/en not_active Expired - Fee Related
- 2011-06-14 HU HUE11730199A patent/HUE026619T2/en unknown
- 2011-06-14 WO PCT/EP2011/002905 patent/WO2011157391A1/en not_active Ceased
- 2011-06-14 EP EP15003060.9A patent/EP2992877A1/en not_active Withdrawn
- 2011-06-14 EP EP11730199.4A patent/EP2582366B1/en not_active Not-in-force
- 2011-06-14 SI SI201130695T patent/SI2582366T1/sl unknown
-
2012
- 2012-09-13 IL IL221926A patent/IL221926A/en active IP Right Grant
- 2012-09-14 CL CL2012002551A patent/CL2012002551A1/es unknown
- 2012-09-14 CO CO12158816A patent/CO6602157A2/es unknown
- 2012-10-03 EC ECSP12012217 patent/ECSP12012217A/es unknown
- 2012-11-16 ZA ZA2012/08646A patent/ZA201208646B/en unknown
-
2013
- 2013-10-02 HK HK16103593.7A patent/HK1215787A1/en unknown
-
2014
- 2014-06-26 US US14/315,603 patent/US20140309311A1/en not_active Abandoned
-
2015
- 2015-07-30 JP JP2015151003A patent/JP6197007B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-14 CY CY20161100034T patent/CY1117118T1/el unknown
- 2016-05-17 RU RU2016119041A patent/RU2675261C2/ru active
- 2016-08-25 AU AU2016219643A patent/AU2016219643B2/en not_active Ceased
-
2017
- 2017-04-05 JP JP2017075145A patent/JP6423036B2/ja not_active Expired - Fee Related
- 2017-08-10 US US15/674,407 patent/US10813890B2/en not_active Expired - Fee Related
-
2019
- 2019-07-02 EC ECSENADI201947259A patent/ECSP19047259A/es unknown